Angelov Angel S 4

What Happened

• Angel S. Angelov, Chief Medical Officer of Vistagen Therapeutics (VTGN), received an award of 150,000 derivative shares reported as a grant on 2026-05-18. The filing lists the transaction as an award/derivative (code A); no exercise price or immediate cash value is disclosed in the Form 4.

Key Details

• Transaction date: 2026-05-18; Form 4 filed: 2026-05-19 (filed timely).
• Shares awarded: 150,000 derivative shares (stock options/award). Price: N/A; total dollar value not disclosed.
• Vesting (footnote): 25% of the options vest on May 18, 2027 (Vesting Start Date); the remaining shares vest monthly at 1/36th of the remainder until fully vested three years after the Vesting Start Date.
• Grant reason (footnote): Award granted in connection with Angelov’s appointment as Chief Medical Officer.
• Shares owned after transaction: not specified in the provided filing.

Context

• This is a compensation grant (derivative award/stock option grant), not an open-market buy or sale. The options must vest per the schedule before they can be exercised; there is no immediate sale or cash proceeds from this grant. Grants tied to new appointments are common executive compensation and do not by themselves indicate a buy/sell market signal.